ArticleTranslational cancer research2025
CST7
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced melanoma exhibits high primary resistance to immunotherapy and limited long-term response, suggesting the need for sensitive biomarkers and novel therapeutic targets to enhance treatment efficacy. We aimed to identify prognostic biomarkers and therapeutic targets for melanoma immunotherapy. Methods: Bulk RNA-sequencing data from public melanoma cohorts were analyzed to classify tumor samples into two clusters based on distinct expression patterns of immune-related hallmarks. Differential gene expression and least absolute shrinkage and selection operator (LASSO) Cox regression analysis identified nine core genes, which were integrated into a prognostic risk model. Single-cell RNA-sequencing analysis was then performed to characterize the immune cell heterogeneity and functional interactions in the tumor microenvironment. Results: The single-cell analysis revealed that CST7 (cystatin F)-expressing macrophages/monocytes were enriched in an M1 macrophage signature, indicative of an antitumor phenotype. These immune cells were significantly more frequent in immunotherapy responders than in non-responders. Further investigation identified a signaling interaction between CST7 Conclusions: These findings suggest that CST7
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.